Tezepelumab for moderate to very severe COPD
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests a new medication called tezepelumab (given as a shot) to see if it can reduce COPD flare-ups in people with moderate to very severe COPD who have had recent flare-ups despite using inhalers. It may be an option for those with higher levels of eosinophils (a type of white blood cell) in their blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old.
- You have had COPD for at least 1 year.
- You have had at least 2 moderate flare-ups or 1 severe flare-up in the past year, and at least one of those flare-ups required steroids.
- You are currently taking a triple or dual inhaler for COPD for at least 3 months.
- Your blood test shows a certain type of white blood cell (eosinophils) count of 150 or higher.
- You are a current or former smoker with at least a 10 pack-year smoking history.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests tezepelumab, an injected medication, for people with moderate to very severe COPD who still have flare-ups despite using standard inhalers. It may help reduce flare-ups and improve breathing for those with higher eosinophil levels.
This study tests whether adding dupilumab (a biologic medication that reduces inflammation) to standard treatment after a severe COPD flare-up requiring hospitalization helps prevent future flare-ups and improves breathing. You may qualify if you were recently hospitalized for COPD with elevated immune markers and have not received certain similar biologic medications recently.
This study tests if tezepelumab can help reduce severe asthma attacks in children ages 5 to 11. It compares the drug to a placebo (a dummy treatment) to see if it is safe and effective.
This study tests if a drug called dupilumab, given as a shot under the skin, can reduce airway inflammation in people aged 40-85 with moderate-to-severe COPD who also have signs of a specific type of inflammation called Type 2. It may help if you have frequent flare-ups and are already using multiple inhalers.
This study tests a drug called tezepelumab for people with severe asthma that is not well controlled with current treatments. It aims to see if adding this drug can reduce asthma attacks and improve symptoms.
This Phase 2 trial tests whether blocking TSLP can reduce inflammation in the airways of people with COPD, especially around flare-ups. If you often need prednisone and/or antibiotics for COPD exacerbations, this study may help determine a new treatment approach.
Hear when a new Chronic Obstructive Pulmonary Disease (COPD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.